NXGL

NexGel, Inc. (NXGL) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This summary covers NexGel, Inc.'s unaudited financial results for the quarter ended March 31, 2026. NexGel manufactures high water content hydrogels for wound care, medical diagnostics, and cosmetics. The company operates through two primary segments: the NexGel segment (manufacturing and branded consumer products) and the CGN JV segment (converting and packaging). The company is classified as a smaller reporting company and an emerging growth company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net revenue decreased 5.6% to $2.65 million, driven primarily by a decline in branded consumer products ($1.62M vs $1.78M), partially offset by growth in Medical Devices/Other ($0.11M vs $0.08M).
• Increased Operating Loss: Loss from operations widened to $0.96 million from $0.78 million due to higher Selling, General, and Administrative (SG&A) expenses ($2.02M vs $1.96M), largely attributed to increased professional and consulting fees.
• Debt Financing: The company issued $1.80 million in Series A Senior Secured Convertible Notes in February 2026, raising $1.62 million in cash proceeds. This significantly increased total liabilities compared to the prior year.
• Cash Position: While total cash and restricted cash increased to $2.12 million, unrestricted cash dropped to $0.21 million. The increase in total cash is largely due to $1.91 million in restricted cash held for partnership advances and project costs.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows from operations. The financial statements do not include adjustments that might be necessary if the company cannot continue operations.
• Strategic Acquisitions: In April 2026 (subsequent to the quarter end but disclosed in notes), the company closed a transaction with Celularity Inc. to acquire a portfolio of regenerative biomaterials, funded by an $8.3 million cash payment and a $5 million convertible note. This transaction is expected to improve liquidity and operating cash flows.
• Capital Strategy: The company plans to explore new product channels in cosmetics and medical devices and may require additional capital raises through debt or equity to fund operations and strategic initiatives.
• Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, specifically regarding the lack of segregation of duties and the absence of proper review controls for journal entries.
• Contingent Liabilities: The company has potential contingent milestone payments of up to $17.5 million to Celularity Inc. upon achieving commercial milestones.

Investor Verification Checklist

• Liquidity Runway: Verify the sufficiency of the $0.21 million unrestricted cash balance against monthly burn rates, given the "Going Concern" warning.
• Debt Conversion Terms: Review the conversion price ($0.60 for Celularity Note; $1.244 for Series A Note) and potential dilution from the $1.8 million convertible note issuance and subsequent conversions.
• Restricted Cash Usage: Confirm the specific contractual terms governing the $1.91 million in restricted cash to understand when these funds become available for general operations.
• Internal Control Remediation: Monitor progress on remediation plans for the identified material weaknesses in financial reporting controls.
• Celularity Integration: Assess the timeline and financial impact of the Celularity asset acquisition and the associated $17.5 million in potential milestone payments.